Serapha Bio
Updated: July 31, 2026
Founder - Rajeev Shah
Country: USA | Funding: $138M (+)
Founded: 2026
Website: https://www.seraphabio.com/
Serapha Bio is a clinical-stage biotechnology company focused on developing a base-editing therapy for Alpha-1 Antitrypsin Deficiency. The company's main asset SERP-01 is being investigated as a potential treatment for alpha-1-antitrypsin deficiency, targets the SERPINA1 E342K mutation. Early clinical data on SERP-01 give hope that this is a potentially best-in-class base editing therapy that can restore AAT to physiologic levels in patients with the most severe form of this disease
Founded: 2026
Website: https://www.seraphabio.com/
Serapha Bio is a clinical-stage biotechnology company focused on developing a base-editing therapy for Alpha-1 Antitrypsin Deficiency. The company's main asset SERP-01 is being investigated as a potential treatment for alpha-1-antitrypsin deficiency, targets the SERPINA1 E342K mutation. Early clinical data on SERP-01 give hope that this is a potentially best-in-class base editing therapy that can restore AAT to physiologic levels in patients with the most severe form of this disease
